InVitae Corp (NYSE:NVTA) COO E Lee Bendekgey sold 21,265 shares of InVitae stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $25.29, for a total value of $537,791.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of InVitae stock traded down $1.13 during midday trading on Thursday, reaching $25.32. The company had a trading volume of 67,533 shares, compared to its average volume of 2,439,517. The stock has a fifty day moving average price of $24.83 and a 200 day moving average price of $21.71. The company has a debt-to-equity ratio of 0.36, a current ratio of 7.18 and a quick ratio of 7.18. The firm has a market cap of $2.45 billion, a PE ratio of -13.07 and a beta of 2.53. InVitae Corp has a fifty-two week low of $9.04 and a fifty-two week high of $28.75.

InVitae (NYSE:NVTA) last issued its earnings results on Tuesday, August 6th. The medical research company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.06). The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $50.17 million. InVitae had a negative return on equity of 58.48% and a negative net margin of 83.69%. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. As a group, sell-side analysts forecast that InVitae Corp will post -2.11 EPS for the current year.

NVTA has been the topic of a number of recent analyst reports. Zacks Investment Research lowered InVitae from a “buy” rating to a “hold” rating in a research note on Friday, April 26th. Leerink Swann set a $31.00 price objective on InVitae and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of InVitae in a research note on Tuesday, June 11th. Benchmark reaffirmed a “buy” rating and issued a $28.00 price objective (up from $26.00) on shares of InVitae in a research note on Wednesday, August 7th. Finally, Oppenheimer set a $34.00 price objective on InVitae and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. InVitae currently has a consensus rating of “Buy” and a consensus target price of $28.17.

Hedge funds have recently modified their holdings of the business. Parallel Advisors LLC bought a new stake in InVitae in the second quarter worth approximately $25,000. PNC Financial Services Group Inc. bought a new stake in InVitae in the first quarter worth approximately $26,000. Certified Advisory Corp bought a new stake in InVitae in the first quarter worth approximately $30,000. First Quadrant L P CA bought a new stake in InVitae in the second quarter worth approximately $36,000. Finally, Signaturefd LLC bought a new stake in InVitae in the first quarter worth approximately $47,000. Institutional investors and hedge funds own 87.51% of the company’s stock.

InVitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Recommended Story: What Factors Can Affect Return on Equity?

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.